Michael A Davies, M.D., Ph.D.

Peer-Reviewed Articles

1. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 82:45-55, 2017. e-Pub 2017. PMID: 28648698.
2. Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE. Association between body mass index, C-reactive protein levels, and melanoma patient outcomes. J Invest Dermatol 137(8):1792-1795, 2017. e-Pub 2017. PMID: 28442307.
3. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28(7):1631-1639, 2017. e-Pub 2017. PMID: 28475671.
4. Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863-873, 2017. e-Pub 2017. PMID: 28592387.
5. Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT. Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases. Clin Cancer Res 23(8):2093-2104, 2017. e-Pub 2016. PMID: 27864417.
6. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF (Non-V600) mutations in cutaneous melanoma patients. Cancer 123(8):1372-1381, 2017. e-Pub 2016. PMID: 27911979.
7. Fiziev P, Akdemir KC, Miller JP, Keung EZ, Samant NS, Sharma S, Natale CA, Terranova CJ, Maitituoheti M, Amin SB, Martinez-Ledesma E, Dhamdhere M, Axelrad JB, Shah A, Cheng CS, Mahadeshwar H, Seth S, Barton MC, Protopopov A, Tsai KY, Davies MA, Garcia BA, Amit I, Chin L, Ernst J, Rai K. Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Rep 19(4):875-889, 2017. PMID: 28445736.
8. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. PMID: 28251903.
9. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2):368-376, 2017. e-Pub 2016. PMID: 27687304.
10. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell 31(2):225-239, 2017. e-Pub 2016. PMID: 28196595.
11. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17(12):1621-1754, 2016. e-Pub 2016. PMID: 27864013.
12. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, *Davies MA, Kluger HM*. Melanoma Central Nervous System Metastases: Current Approaches, Challenges, and Opportunities. Pigment Cell Melanoma Res 29(6):627-642, 2016. e-Pub 2016. PMID: 27615400 (*contributed equally).
13. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
14. Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma. Cancer Res 76(18):5455-66, 2016. e-Pub 2016. PMID: 27488531.
15. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2(8):1056-64, 2016. e-Pub 2016. PMID: 27124486.
16. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
17. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The State of Melanoma: Challenges and Opportunities. Pigment Cell Melanoma Res 29(4):404-16, 2016. e-Pub 2016. PMID: 27087480.
18. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res 22(12):3016-24, 2016. e-Pub 2016. PMID: 26783288.
19. Goedert L, Pereira CG, Roszik J, Plaça JR, Cardoso C, Chen G, Deng W, Yennu-Nanda VG, Silva WA, Davies MA, Espreafico EM. RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. Oncotarget 7(24):36711-36718, 2016. e-Pub 2016. PMID: 27167340.
20. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5):1834-56, 2016. e-Pub 2016. PMID: 27043285.
21. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
22. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, *Davies MA, *Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2015. PMID: 26645196 (*contributed equally).
23. Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep 6:19649, 2016. e-Pub 2016. PMID: 26787600.
24. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst 108(6):djv426, 2016. e-Pub 2016. PMID: 26819345.
25. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL. AKT1 Activation Promotes Development of Melanoma Metastases. Cell Rep 13(5):898-905, 2015. e-Pub 2015. PMID: 26565903.
26. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-62, 2015. e-Pub 2015. PMID: 26014291.
27. Vu HL, Rosenbaum S, Purwin TJ, Davies MA, Aplin AE. RAC1 P29S regulates PD-L1 expression in melanoma. Pigment Cell Melanoma Res 28(5):590-8, 2015. e-Pub 2015. PMID: 26176707.
28. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas. Cancer Res 75(15):3554-67, 2015. e-Pub 2015. PMID: 26206558.
29. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
30. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 21(11):2644-51, 2015. e-Pub 2015. PMID: 25695693.
31. Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, Davies MA, Hwu P, Lizée G. BRAF(V600E) co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. Cancer Immunol Res 3(6):602-9, 2015. e-Pub 2015. PMID: 25795007.
32. Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681-96, 2015. PMID: 26091043.
33. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2014. PMID: 25148578.
34. Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 activation blocks Braf V600E - induced growth arrest, but is insufficient for melanoma formation. Cancer Cell 27(1):41-56, 2015. PMID: 25584893.
35. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Inhibition of mTORC1/2 overcomes PGC1a and OxPhos-mediated resistance. Cancer Res 74(23):7037-47, 2014. e-Pub 2014. PMID: 25297634.
36. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clin Cancer Res 20(21):5537-46, 2014. e-Pub 2014. PMID: 24803579.
37. Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, Davies MA. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res 20(21):5527-36, 2014. e-Pub 2014. PMID: 25165098.
38. Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai KY, Davies MA, Mills GB, Chin L. The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. Cancer Res 74(17):4845-4852, 2014. e-Pub 2014. PMID: 25056119.
39. Kugel CH, Hartsough EJ, Davies MA, Setiady YY, Aplin AE. Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. Cancer Res 74(15):4122-32, 2014. e-Pub 2014. PMID: 25035390.
40. Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y. A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget 5(10):2912-7, 2014. PMID: 24913145.
41. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK. Targeting ER stress induced-autophagy overcomes resistance to BRAF inhibition in melanoma. J Clin Invest 124(3):1406-17, 2014. e-Pub 2014. PMID: 24569374.
42. Prickett TD, Zerlanko B, Gartner JJ, Parker SC, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, NISC Comparative Sequencing Program, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y. Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. J Invest Dermatol 134(2):452-60, 2014. e-Pub 2013. PMID: 24008424.
43. Curry JL, Davies MA, Calderone TL, Nathanson K, Prieto VG, Gershenwald JE. Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol 1102:679-95, 2014. PMID: 24259006.
44. Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale. PLoS One 9(7):e101286, 2014. e-Pub 2014. PMID: 24983357.
45. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119(21):3821-9, 2013. e-Pub 2013. PMID: 23922205.
46. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, O'Day S, Infante JR, Falchook GS, Arkenau HT, Millward M, Brown MP, Pavlick A, Davies MA, Ma B, Gagnon R, Curtis CM, Lebowitz PF, Kefford RF, Long GV. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF ihibitor Dabrafenib (GSK2118436). Clin Cancer Res 19(17):4868-78, 2013. e-Pub 2013. PMID: 23833299.
47. Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, Davies MA, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer 109(5):1085-92, 2013. e-Pub 2013. PMID: 23942080.
48. Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK, NISC Comparative Sequencing Program, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110(33):13481-6, 2013. e-Pub 2013. PMID: 23901115.
49. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. J Mol Diagn 15(2):220-6, 2013. e-Pub 2012. PMID: 23273605.
50. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. Clin Cancer Res 19(3):657-667, 2013. e-Pub 2012. PMID: 23251002.
51. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087-95, 2012. e-Pub 2012. PMID: 23051966.
52. Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. J Immunother 35(9):711-715, 2012. PMID: 23090080.
53. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clin Cancer Res 18(19):5329-40, 2012. e-Pub 2012. PMID: 22850568.
54. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, Lazar AJ, Davies MA. NRAS mutation status is an independent prognostic factor in Metastatic Melanoma. Cancer - Am Cancer Soc 118(16):4014-23, 2012. e-Pub 2011. PMID: 22180178.
55. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ and GNA11 dependant manner. Clin Cancer Res 18(16):4345-55, 2012. e-Pub 2012. PMID: 22733540.
56. Alvarado G, Noor R, Basset R, Papadopoulos NE Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310-5, 2012. PMID: 22584956.
57. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A Landscape of Driver Mutations in Melanoma. Cell 150(2):251-263, 2012. PMID: 22817889.
58. Deng W, Yennu-Nanda VG, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTor in de novo resistance to BRAF inhibition. Pigm Cell Melanoma Res 25(2):248-58, 2012. e-Pub 2012. PMID: 22171948.
59. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng C, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res 18(4):1120-8, 2012. e-Pub 2012. PMID: 22223528.
60. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA. Correlation of NRAS mutations with clinical response to high dose IL-2 in patients with advanced melanoma. J Immunother 35(1):66-72, 2012. PMID: 22130161.
61. Prickett TD, Wei X, Teer J, Cherukuri PF, Lin, JC, Molinolo A, Rosenberg SA, Davies MA, Gershenwald JE, Stemke-Hale K, Margulies EH, Samuels Y. Exon Capture Analysis of G-Protein Coupled Receptors Reveals Activating Mutatinos in GRM3 in Melanoma. Nat Genet 43(11):1119-26, 2011. e-Pub 2011. PMID: 21946352.
62. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. Cancer - Am Cancer Soc 117(8):1687-96, 2011. e-Pub 2010. PMID: 20960525.
63. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736-8747, 2010. e-Pub 2010. PMID: 20959481.
64. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9(2):257-67, 2010. e-Pub 2010. PMID: 20124458.
65. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15(24):7538-7546, 2009. PMID: 19996208.
66. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Vashisht Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of Dasatinib Against L576P KIT Mutant Melanoma: Molecular, Cellular, and Clinical Correlates. Mol Cancer Ther 8(8):2079-85, 2009. e-Pub 2009. PMID: 19671763.
67. Vasudevan KM*, Barbie DA*, Davies MA*, Rabinovsky R, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, McNear CJ, Sandy P, Hoesch S, Sheng Q, Gupta P, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer *Featured on Cover. Cancer Cell 16(1):21-32, 2009. PMID: 19573809 (*contributed equally).
68. Aziz SA, Davies MA, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res 15(9):3029-36, 2009. e-Pub 2009. PMID: 19383818.
69. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Brit J Cancer 99(8):1265-1268, 2008. PMID: 18813315.
70. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8(6):1904-1914, 2002. PMID: 12060635.
71. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59(11):2551-6, 1999. PMID: 10363971.
72. Delehedde M, Cho SH, Sarkiss M, Brisbay S, Davies MA, El-Naggar AK, McDonnell TJ. Altered expression of bcl-2 family member proteins in nonmelanoma skin cancer. Cancer 85(7):1514-22, 1999. PMID: 10193941.
73. Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58(23):5285-90, 1998. PMID: 9850049.
74. Vettus E, Draper D, Davies MA. Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy After Progression on Ipilimumab and Nivolumab Immunotherapy. Annals of Clinical Case Reports. e-Pub 2017.
75. Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK. Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatol. e-Pub 2016. PMID: 27829081.

Invited Articles

1. Glitza Oliva I, Tawbi H, Davies MA. Melanoma brain metastases: current areas of investigation and future directions. Cancer J 23(1):68-74, 2017. PMID: 28114258.
2. Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, Davies MA, Lazar AJ. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. J Natl Compr Canc Netw 14(6):787-92, 2016. PMID: 27283170.
3. Davies MA. Molecular Approaches to Tumor Inhibition in Melanoma. Clinical Advances in Hematology & Oncology 13(12), 2015. PMID: 27058849.
4. Davies MA. Role and complexity of next-generation sequencing in melanoma. Cancer Cytopathol 123(6):329-30, 2015. e-Pub 2015. PMID: 25877344.
5. McQuade J, Davies MA. Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag 2(3):241-254, 2015. PMID: 26594316.
6. Glitza IC, Davies MA. Genotyping of Cutaneous Melanoma. Chin Clin Oncol 3(3):27, 2014. PMID: 25632386.
7. Chen G, Davies MA. Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. Hematology/Oncology Clinics of North America 28(3):523-536, 2014. PMID: 24880945.
8. Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget 5(7):1701-52, 2014. e-Pub 2014. PMID: 24743024.
9. Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 87(3):381-9, 2014. e-Pub 2013. PMID: 24291778.
10. Davies MA. Targeted Therapy for Cutaneous Melanoma: Beyond. J Patient-Centered Res Rev 1(1):12-20, 2014.
11. Kwong LN, Davies MA. Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. Clin Cancer Res 19(19):5310-9, 2013. PMID: 24089444.
12. Kwong LN, Davies MA. Targeted Therapy for Melanoma: Rational Combinatorial Approaches. Oncogene, 2013. e-Pub 2013. PMID: 23416974.
13. Davies MA. The Role of the PI3K-AKT Pathway in Melanoma. Cancer J 18(2):142-7, 2012. PMID: 22453015.
14. Woodman SE, Lazar AJ, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clin Cancer Res 18(5):1195-200, 2012. e-Pub 2012. PMID: 22275506.
15. Davies MA. Targeted Therapy for Brain Metastases. Adv Pharmacol 65:109-42, 2012. PMID: 22959025.
16. Davies MA. Regulation, Role, and Targeting of AKT in Cancer. J Clin Oncol 29(35):4715-7, 2011. e-Pub 2011. PMID: 22025159.
17. Woodman SE,Davies MA. Targeting KIT in Melanoma: A Paradigm of Molecular Medicine and Targeted Therapeutics. Biochem Pharmacol 80(5):568-74, 2010. e-Pub 2010. PMID: 20457136.

Editorials

1. Davies MA. Finding the Right Balance of BRAF Inhibition in Melanoma. Cancer Discov 4(5):510-2, 2014. PMID: 24795008.

Abstracts

1. Davies MA, Robert C, Long GV, Grob JJ, Flaherty KT, Arance A, Sileni-Chiarion V, Thomas L, Lesimple T, Mortier L, Moschos S, Hogg D, Rodas IM, Del Vecchio M, Lebbe C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Saiag P. COMBI-MB: a phase 2 study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). ASCO Annual Meeting 2017, 2017.
2. Menzies AM, Rozeman EA, Amaria RN, Scolyer RA, Tetzlaff MT, Guminski A, Davies MA, Blank CU, Wargo JA, Long GV. Preliminary results from the international neoadjuvant melanoma consortium (INMC). ASCO Annual Meeting 2017, 2017.
3. Schvartsman G, Ma J, Bassett RL Jr., Haydu LE, Amaria RN, Hwu P, Hwu WJ, Diab A, Patel SP, Davies MA, Tawbi HAH. Incidence, patterns of progression and outcomes of melanoma brain metastasis (MBM) during programmed-death 1 inhibitor (PD1i) therapy. ASCO Annual Meeting 2017, 2017.
4. Maria, RN, Prieto P, Tetzlaff M, Diab A, Patel S, Woodman SE, Hwu WJ, Glitza IC, Hwu P, Tawbi H, McQuade JL, Cormier J, Lucci A, Royal R, Lee J, Bassett R, Simpson L, Burton EM, Grimm EA, Reuben A, Spencer C, Gershenwald JE, Ross M, Davies MA, Wargo JA. Treatment with neoadjuvant + adjuvant dabrafenib and trametinib (D+T) is associated with imporoved relapse-free survival (RFS versus standard of care (SOC) therapy in ptients with high-risk resectable BRAF-mutant melanoma. 2016 SMR Congress, 2016.
5. McQuade JL, Wang DY, Rai R, Park J, Spencer C, McKean M, Beckermann K, Nahar K, Rubinstein S, Guminski A, Lo S, Sosman JA, Wargo JA, Daniel C, Long GV, Hwu P Hess K, Carlin MS, Menzies A, Johnson DB, Davies MA. High body mass index (BMI) is associated with improved clinical outcomes in metastatic melanoma patients treated with anti-PD1: differences by gender. 2016 SMR Congress, 2016.
6. Flaherty K, Davies MA, Grob JJ, Long DV, Nathan PD, Ribas A, Robert C, Schadendorf D, Frederick DT, Hammond MR, Valbuena-Jane J, Mu XJ, Squires M, Jaeger SA, Lane ST, Mookerjee B, Garraway LA. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. ASCO Annual Meeting 2016, 2016.
7. McQuade JL, Haydu LE, Frankian S, Spencer C, Long GV, Brob JJ, Lane SR, Legenne P, Flaherty K, Hwu P, Hess KR, Davies MA. The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib. ASCO Annual Meeting 2016, 2016.
8. Bedard PL, Davies MA, Kopetz S, Flaherty KT, Shapiro G, Luke JJ, Spreafico A, Wu B, Gomez C, Cartot-Cotton S, Mazuir F, Micallef S, Demers B, Juric D,. First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). ASCO Annual Meeting 2015, 2015.
9. Kemnade J, Roszik J, Joon A, Stingo F, Baladandayuthapani V, Lazar AJF, Woodman SE, Davies MA. Identification of potentially actionable mutations in RTKs in melanoma detected by next generation sequencing (NGS). ASCO Annual Meeting 2015, 2015.
10. Joon A, Haydu L, Baladandayuthapani V, Stingo F, Woodman S, Amaria A, Wargo J, shaw K, Meric-Bernstam F, Mills G, Gershenwald J, Hwu P, Lazar a, Davies MA. Next generation sequencing of 201 cancer-related genes in melanoma. Society for Melanoma Research 2014 Congress, 2014.
11. Yorio JT, Bucheit AD, McIntyre S, Fox P, Bassett R, Davies MA. Toxicities and outcomes in metastatic melanoma patients (pts) treated with Ipilimumab (Ipi) and BRAF inhibitors (BRAFi). Society for Melanoma Research Meeting, 2013.
12. Davies MA. Molecular and clinical correlates of PTEN expression in melanoma. AACR Annual Meeting 2012, 2012.
13. Jakob JA, Bassett RL, Ng CS, Lazar AJF, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, Davies MA. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. 2011 ASCO Annual Meeting, 2011.
14. Joseph RW, Hwu P, Davies MA, Atkins MB, Sullivan RJ. Clinical benefit of ipilmumab in patients with metastatic melanoma who progress on high dose IL-2. 2011 ASCO Annual Meeting, 2011.

Book Chapters

1. Siroy AE, Davies MA , Lazar AJ. The PI3K-AKT Pathway in Melanoma. In: Genetics of Melanoma. Cancer Genetics: New York, 165-180, 2016.
2. Davies MA. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma. In: BRAF Targets in Melanoma. Humana Press: Maryland, 105.135, 2015.
3. Davies MA, Garraway LA. Molecular Biology of Cutaneous Melanoma. In: Cancer Principles & Practice of Oncology. 10th. Wolters Kluwer, 1337-1345, 2015.
4. Kupferman ME, Davies MA. Melanoma of the Head and Neck: General Principles and Management. In: Head and Neck Cancer A Multidisciplinary Approach. 4th. Wolters Kluwer Lippincott Williams & Wilkins, 672-691, 2013.
5. Ahmed KB, Davies MA. New Molecular Targets for Systemic Therapy of Melanoma. In: Research on Melanoma - A Glimpse into Current Directions and Future Trends,. InTech - Open Access Publisher, 161-180, 2011.
6. Kim KB, Davies MA, Rapini RP, Hwu P, Bedikian AY. Malignant Melanoma. In: The MD Anderson Manual of Medical Oncology, Second Edition. 2nd. McGraw Hill: China, 1077-1109, 2011.
7. Davies MA, Patel S, Kim K. Targeted Therapy in Melanoma. In: Targeted Therapy in Cancer. 1. Humana Press: Totowa, NJ, 183-211, 2008.